Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 19, Issue 2, Pages 241-244Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458512444915
Keywords
magnetization transfer; multiple sclerosis; alemtuzumab
Categories
Funding
- Genzyme Corporation
- Bayer Schering Pharma
- Cambridge Biomedical Centre
- UK MS Society
- UCLH/UCL Biomedical Research Centre
- National Institute for Health Research [NF-SI-0508-10058, NF-SI-0508-10335] Funding Source: researchfish
Ask authors/readers for more resources
The magnetization transfer ratio reflects the integrity of tissue structure, including myelination and axonal density. Mean magnetization transfer ratio fell in 18 untreated patients with multiple sclerosis both in normal appearing grey (-0.25 pu/year, p < 0.001) and white matter (-0.12 pu/year, p = 0.004). Conversely, mean magnetization transfer ratio was stable in 20 alemtuzumab-treated patients (grey matter: -0.01 pu/year, p = 0.87; white matter: -0.02 pu/year, p = 0.51). The gradient difference in grey matter was 0.25 pu/year < 0.001) after age-adjustment. These data suggest that in multiple sclerosis alemtuzumab protects against tissue damage in normal-appearing grey matter, perhaps by preventing new lesion formation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available